ATE177841T1 - ''crosstalk''- oder übersprech-inhibitoren und ihre verwendung - Google Patents

''crosstalk''- oder übersprech-inhibitoren und ihre verwendung

Info

Publication number
ATE177841T1
ATE177841T1 AT92910790T AT92910790T ATE177841T1 AT E177841 T1 ATE177841 T1 AT E177841T1 AT 92910790 T AT92910790 T AT 92910790T AT 92910790 T AT92910790 T AT 92910790T AT E177841 T1 ATE177841 T1 AT E177841T1
Authority
AT
Austria
Prior art keywords
ligand
crosstalk
binding
assay
analogue conjugate
Prior art date
Application number
AT92910790T
Other languages
English (en)
Inventor
Kenneth Francis Buechler
Richard Ray Anderson
Theodore Tsan-Tsung Lee
Gunars Edwin Valkirs
Original Assignee
Biosite Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosite Diagnostics Inc filed Critical Biosite Diagnostics Inc
Application granted granted Critical
Publication of ATE177841T1 publication Critical patent/ATE177841T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/962—Prevention or removal of interfering materials or reactants or other treatment to enhance results, e.g. determining or preventing nonspecific binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds
    • Y10S436/816—Alkaloids, amphetamines, and barbiturates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds
    • Y10S436/817—Steroids or hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/822—Identified hapten

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Photolithography (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Stereophonic System (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Communication Cables (AREA)
  • Pyrrole Compounds (AREA)
AT92910790T 1991-04-10 1992-04-07 ''crosstalk''- oder übersprech-inhibitoren und ihre verwendung ATE177841T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68345691A 1991-04-10 1991-04-10

Publications (1)

Publication Number Publication Date
ATE177841T1 true ATE177841T1 (de) 1999-04-15

Family

ID=24744132

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92910790T ATE177841T1 (de) 1991-04-10 1992-04-07 ''crosstalk''- oder übersprech-inhibitoren und ihre verwendung

Country Status (10)

Country Link
US (1) US5525524A (de)
EP (1) EP0585310B1 (de)
JP (1) JPH06506688A (de)
AT (1) ATE177841T1 (de)
AU (1) AU1772992A (de)
CA (1) CA2107894C (de)
DE (1) DE69228682T2 (de)
FI (1) FI934437L (de)
NO (1) NO933581L (de)
WO (1) WO1992018868A1 (de)

Families Citing this family (187)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994103A (en) * 1995-06-02 1999-11-30 Human Genome Science, Inc. Human stanniocalcin-alpha
FR2751989B1 (fr) * 1996-08-01 1998-10-30 Soc D Rech Et De Dev En Activa Methode d'identification de cellules eucaryotes par fixation desdites cellules sur un support et support pour mettre en oeuvre ladite methode
US6544797B1 (en) 1997-04-09 2003-04-08 Biosite Diagnostics, Inc. Compositions and methods for inhibiting light-induced inactivation of biological reagents
US6392894B1 (en) 1998-01-05 2002-05-21 Biosite Incorporated Media carrier for an assay device
US6830731B1 (en) * 1998-01-05 2004-12-14 Biosite, Inc. Immunoassay fluorometer
US6096726A (en) * 1998-03-11 2000-08-01 Surface Solutions Laboratories Incorporated Multicomponent complex for use with substrate
ES2390425T3 (es) 2000-12-22 2012-11-12 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Uso de moléculas de orientación repulsivas (RGM) y sus moduladores
US20040203083A1 (en) * 2001-04-13 2004-10-14 Biosite, Inc. Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases
US20040126767A1 (en) * 2002-12-27 2004-07-01 Biosite Incorporated Method and system for disease detection using marker combinations
US20030219734A1 (en) * 2001-04-13 2003-11-27 Biosite Incorporated Polypeptides related to natriuretic peptides and methods of their identification and use
US7632647B2 (en) * 2001-04-13 2009-12-15 Biosite Incorporated Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US7524635B2 (en) * 2003-04-17 2009-04-28 Biosite Incorporated Methods and compositions for measuring natriuretic peptides and uses thereof
US20030199000A1 (en) * 2001-08-20 2003-10-23 Valkirs Gunars E. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US20040253637A1 (en) * 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US20040121350A1 (en) * 2002-12-24 2004-06-24 Biosite Incorporated System and method for identifying a panel of indicators
WO2003016910A1 (en) * 2001-08-20 2003-02-27 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
JP3806694B2 (ja) 2001-05-04 2006-08-09 バイオサイト インコーポレイテッド 急性冠状動脈症候群の診断マーカーおよびその使用方法
US20040219509A1 (en) * 2001-08-20 2004-11-04 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
WO2004094460A2 (en) 2003-04-17 2004-11-04 Ciphergen Biosystems, Inc. Polypeptides related to natriuretic peptides and methods of their identification and use
JP2007518062A (ja) * 2003-09-29 2007-07-05 バイオサイト インコーポレイテッド 敗血症を診断する方法および診断するための組成物
EP1706743B1 (de) 2003-12-12 2009-11-18 Inverness Medical Switzerland GmbH Assay
US20050130243A1 (en) * 2003-12-15 2005-06-16 Zheng Yi F. Assay for entactogens
US7022492B2 (en) * 2003-12-15 2006-04-04 Dade Behring Inc. Ecstasy haptens and immunogens
US6991911B2 (en) * 2003-12-15 2006-01-31 Dade Behring Inc. Assay for entactogens
US7037669B2 (en) * 2004-03-22 2006-05-02 Dade Behring Inc. Assays for amphetamine and methamphetamine using stereospecific reagents
US7115383B2 (en) * 2004-03-22 2006-10-03 Dade Behring Inc. Assays for amphetamine and methamphetamine
US20060105419A1 (en) * 2004-08-16 2006-05-18 Biosite, Inc. Use of a glutathione peroxidase 1 as a marker in cardiovascular conditions
JP4581571B2 (ja) * 2004-09-06 2010-11-17 富士ゼロックス株式会社 粒子のマレイミジル基量を測定する定量方法
WO2006031583A2 (en) * 2004-09-09 2006-03-23 Biosite Incorporated Methods and compositions for measuring canine bnp and uses thereof
US20060084184A1 (en) * 2004-10-19 2006-04-20 Renovar Incorporated Reagents for urine-based immunological assays
US20080050832A1 (en) * 2004-12-23 2008-02-28 Buechler Kenneth F Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
WO2006078813A2 (en) * 2005-01-21 2006-07-27 Biosite Incorporated Arginine analogs, and methods for their synthesis and use
WO2006135781A2 (en) * 2005-06-09 2006-12-21 Biosite, Inc. Methods and compositions for the diagnosis of venous thromboembolic disease
EP1929295A4 (de) * 2005-08-30 2010-03-17 Biosite Inc Verwendung von löslichem flt-1 und seiner fragmente bei herz-kreislauf-leiden
CN101277974A (zh) 2005-09-30 2008-10-01 阿伯特有限及两合公司 排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
US20070224643A1 (en) * 2006-03-09 2007-09-27 Mcpherson Paul H Methods and compositions for the diagnosis of diseases of the aorta
US20080118924A1 (en) * 2006-05-26 2008-05-22 Buechler Kenneth F Use of natriuretic peptides as diagnostic and prognostic indicators in vascular diseases
GB0611116D0 (en) 2006-06-06 2006-07-19 Oxford Genome Sciences Uk Ltd Proteins
ATE528411T1 (de) 2006-06-07 2011-10-15 Otago Innovation Ltd Diagnoseverfahren und -marker
CN101495868A (zh) * 2006-07-28 2009-07-29 博适公司 利用磁性颗粒进行受体结合试验的装置和方法
WO2008030122A1 (en) 2006-09-07 2008-03-13 University Of Otago Biomarkers
US8524462B2 (en) * 2006-11-14 2013-09-03 Alere San Diego, Inc. Methods and compositions for diagnosis and prognosis of renal artery stenosis
US7842472B2 (en) 2006-11-14 2010-11-30 Alere International Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
US8221995B2 (en) * 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US20090004755A1 (en) * 2007-03-23 2009-01-01 Biosite, Incorporated Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US7903970B2 (en) * 2007-03-30 2011-03-08 Georgia Tech Research Corporation Optical network evaluation systems and methods
US7947465B2 (en) * 2007-08-20 2011-05-24 Bio-Rad Laboratories, Inc. Simultaneous assay for determining drugs
US20090053832A1 (en) * 2007-08-20 2009-02-26 Link William F Simultaneous assay for determining drugs
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
ES2666725T3 (es) * 2008-03-12 2018-05-07 Otago Innovation Limited Biomarcadores
JP2011516038A (ja) 2008-03-12 2011-05-26 オタゴ イノベーション リミテッド バイオマーカー
BRPI0917711A2 (pt) 2008-08-28 2017-06-20 Astute Medical Inc método para avaliar o estado renal em um paciente, e, uso de um ou mais marcadores de lesão renal
WO2010025434A1 (en) 2008-08-29 2010-03-04 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN106370857A (zh) 2008-10-21 2017-02-01 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
CN104076152B (zh) 2008-10-21 2017-04-19 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
JP5752600B2 (ja) 2008-11-10 2015-07-22 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後のための方法
CN103439510B (zh) 2008-11-22 2016-09-14 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
US20100204055A1 (en) * 2008-12-05 2010-08-12 Bonner-Ferraby Phoebe W Autoantibody detection systems and methods
EP2394166B1 (de) 2009-02-06 2016-07-13 Astute Medical, Inc. Verfahren zur diagnose und prognose von nierenläsion und niereninsuffizienz
CA2751430A1 (en) 2009-02-06 2010-08-12 Astute Medical, Inc. Diagnosis and prognosis of renal injury and renal failure
CA2767616A1 (en) 2009-07-09 2011-01-13 The Scripps Research Institute Gene expression profiles associated with chronic allograft nephropathy
EP2462446B1 (de) 2009-08-07 2017-09-27 Astute Medical, Inc. Verfahren und zusammensetzungen zur diagnose und prognose von nierenverletzungen und niereninsuffizienz
US8871459B2 (en) 2009-08-07 2014-10-28 Astute Medical, Inc. Method for evaluating renal status by determining beta-2-glycoprotein 1
CN102792161B (zh) 2009-08-28 2014-11-12 阿斯图特医药公司 肾损伤和肾衰竭的诊断及预后的方法及组合物
EA201290106A1 (ru) 2009-09-18 2012-12-28 Астьют Медикал, Инк. Способы и композиции для диагностики и прогнозирования повреждения почек и почечной недостаточности
CA2774223A1 (en) 2009-09-21 2011-03-24 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ599773A (en) 2009-11-07 2014-09-26 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ624614A (en) 2009-11-07 2015-10-30 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
KR20120118002A (ko) * 2009-12-08 2012-10-25 애보트 게엠베하 운트 콤파니 카게 망막 신경 섬유 층 변성의 치료에 사용하기 위한 ｒｇｍ ａ 단백질에 대한 모노클로날 항체
CN102725636B (zh) 2009-12-20 2015-04-01 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
CA2788829A1 (en) 2010-02-05 2011-08-11 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2788826C (en) 2010-02-05 2023-09-26 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20130005601A1 (en) 2010-02-05 2013-01-03 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2011311997A1 (en) 2010-02-26 2013-04-04 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2539712A4 (de) 2010-02-26 2013-09-18 Astute Medical Inc Verfahren und zusammensetzungen zur diagnose und prognose von nierenverletzungen und niereninsuffizienz
WO2011162819A1 (en) 2010-06-23 2011-12-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP5786020B2 (ja) 2010-04-16 2015-09-30 アボットジャパン株式会社 関節リウマチを診断する方法および試薬
CA2803500A1 (en) 2010-06-23 2011-12-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ605698A (en) 2010-06-23 2015-03-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ707637A (en) 2010-07-19 2016-09-30 Otago Innovation Ltd Signal biomarkers
BR112013006631A2 (pt) 2010-09-24 2017-10-24 Astute Medical Inc métodos e composições para a avaliação de lesão renal utilizando ácido hialurônico
US10557856B2 (en) 2010-09-24 2020-02-11 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Biomarkers of renal injury
US8795975B2 (en) 2010-11-29 2014-08-05 Alere San Diego, Inc. Methods and compositions for diagnosis and risk prediction in heart failure
CA2824434A1 (en) 2011-01-08 2012-07-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2012102963A1 (en) 2011-01-26 2012-08-02 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Urine biomarkers for prediction of recovery after acute kidney injury : proteomics
EP2668499A4 (de) 2011-01-29 2015-05-27 Astute Medical Inc Verfahren und zusammensetzungen zur diagnose und prognose von nierenverletzungen und niereninsuffizienz
WO2013002309A1 (ja) * 2011-06-29 2013-01-03 三菱化学メディエンス株式会社 非特異反応抑制剤、非特異反応抑制方法及びキット
PT2748605T (pt) 2011-08-26 2019-05-03 Astute Medical Inc Processos e composições para o diagnóstico e o prognóstico de lesões renais e de insuficiência renal
US20140315752A1 (en) 2011-11-22 2014-10-23 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2013086359A1 (en) 2011-12-08 2013-06-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN104144947B (zh) 2011-12-14 2017-10-27 艾伯维德国有限责任两合公司 用于诊断和治疗铁相关病症的组合物和方法
EP2791175A2 (de) 2011-12-14 2014-10-22 Abbvie Deutschland GmbH & Co. KG Zusammensetzung und verfahren zur diagnose und behandlung von durch eisenmangel bedingten erkrankungen
EP3369746A1 (de) 2012-01-27 2018-09-05 AbbVie Deutschland GmbH & Co KG Zusammensetzung und verfahren zur diagnose und behandlung von krankheiten im zusammenhang mit neuritenabbau
CA2865563A1 (en) 2012-02-27 2013-09-06 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
BR112014018717A8 (pt) 2012-03-13 2017-07-11 Abbvie Inc Método para selecionar ou identificar um sujeito para terapia de antagonista de v1b
WO2013141716A1 (en) 2012-03-20 2013-09-26 Christopher Joseph Pemberton Biomarkers
US20150293131A1 (en) 2012-04-02 2015-10-15 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of sepsis
US9733261B2 (en) 2012-04-24 2017-08-15 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of stroke or other cerebral injury
WO2014018464A1 (en) 2012-07-23 2014-01-30 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of sepsis
WO2014028339A1 (en) 2012-08-11 2014-02-20 Astute Medical, Inc. Evaluating renal injury using hyaluronic acid
JP6681195B2 (ja) 2013-01-17 2020-04-15 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
AU2014239248B2 (en) 2013-03-14 2017-02-23 Alere San Diego, Inc. 6-Acetylmorphine analogs, and methods for their synthesis and use
US9469686B2 (en) 2013-03-15 2016-10-18 Abbott Laboratories Anti-GP73 monoclonal antibodies and methods of obtaining the same
WO2014197729A1 (en) 2013-06-05 2014-12-11 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2014197885A2 (en) 2013-06-07 2014-12-11 Duke University Inhibitors of complement factor h
WO2015021308A1 (en) 2013-08-07 2015-02-12 Astute Medical, Inc. Assays for timp2 having improved performance in biological samples
NZ774222A (en) 2013-08-23 2023-01-27 Reata Pharmaceuticals Holdings Llc Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
WO2015031626A1 (en) 2013-08-28 2015-03-05 Abbvie Inc. Soluble cmet assay
CN105556308B (zh) 2013-09-20 2018-05-29 阿斯图特医药公司 用于阑尾炎的诊断和预后及腹痛病因的区分的方法和组合物
US9822172B2 (en) 2013-11-06 2017-11-21 Astute Medical, Inc. Assays for IGFBP7 having improved performance in biological samples
CN110007084B (zh) 2013-12-03 2022-11-18 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断和预后的方法和组合物
JP2017506910A (ja) 2013-12-30 2017-03-16 ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド 前立腺癌に関連したゲノム再編成及び該ゲノム再編成の使用方法
EP3146076A4 (de) 2014-05-22 2018-05-09 The Scripps Research Institute Mit subklinischer nierentransplantatabstossung assoziierte genexpressionsprofile
EP3146077A4 (de) 2014-05-22 2018-05-02 The Scripps Research Institute Molekulare gewebesignaturen von nierentransplantatabstossungen
WO2015179771A2 (en) 2014-05-22 2015-11-26 The Scripps Research Institute Molecular signatures for distinguishing liver transplant rejections or injuries
US11104951B2 (en) 2014-05-22 2021-08-31 The Scripps Research Institute Molecular signatures for distinguishing liver transplant rejections or injuries
US10443100B2 (en) 2014-05-22 2019-10-15 The Scripps Research Institute Gene expression profiles associated with sub-clinical kidney transplant rejection
KR102431003B1 (ko) 2014-10-20 2022-08-09 아스튜트 메디컬 인코포레이티드 신손상 및 신부전의 진단 및 예후를 위한 방법 및 조성물
WO2016100912A1 (en) 2014-12-18 2016-06-23 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US11243202B2 (en) 2015-04-09 2022-02-08 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP2018521307A (ja) 2015-05-12 2018-08-02 アスチュート メディカル，インコーポレイテッド 腎障害および腎不全の診断および予後のための方法および組成物
HK1248808A1 (zh) 2015-06-11 2018-10-19 阿斯图特医药公司 用於肾损伤和肾衰竭的诊断和预後的方法和组合物
WO2016205740A1 (en) 2015-06-17 2016-12-22 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of appendicitis and differentiation of causes of abdominal pain
CA2992139A1 (en) 2015-07-10 2017-01-19 West Virginia University Markers of stroke and stroke severity
EP3458439B1 (de) 2016-05-18 2021-12-08 Alere San Diego, Inc. 2-ethyliden-1,5-dimethyl-3,3-diphenylpyrrolidin-analoga sowie methoden zu deren synthese und verwendung
CN109844526A (zh) 2016-06-06 2019-06-04 机敏医药股份有限公司 使用胰岛素样生长因子结合蛋白7和金属蛋白酶2的组织抑制剂管理急性肾损伤
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
EP4521116A3 (de) 2016-10-03 2025-05-28 Abbott Laboratories Verbesserte verfahren zur beurteilung des uch-l1-status in patientenproben
WO2018067730A1 (en) 2016-10-04 2018-04-12 University Of Maryland, Baltimore Methods of treating sepsis using anti-sepsis lipid a (asla) based therapeutics
AU2017356955B2 (en) 2016-11-08 2023-11-09 Reata Pharmaceuticals Holdings, LLC Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof
MX2019008260A (es) 2017-01-12 2020-01-27 Astute Medical Inc Metodos y composiciones para la evaluacion y tratamiento de lesion renal e insuficiencia renal con base en la medicion del ligando 14 de quimiocina de la porcion c-c.
JP2020511674A (ja) 2017-03-09 2020-04-16 クリラ バイオテック ベー．フェー． 細胞老化バイオマーカー
CA3261113A1 (en) 2017-03-23 2025-10-27 Abbott Laboratories Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
CN110546513A (zh) 2017-04-15 2019-12-06 雅培实验室 使用早期生物标记物帮助超急性诊断和确定人类受试者中的创伤性脑损伤的方法
ES3053676T3 (en) 2017-04-28 2026-01-23 Abbott Lab Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
WO2018208684A1 (en) 2017-05-07 2018-11-15 Astute Medical, Inc. Use of insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2 in the management of renal replacement therapy
AU2018272054B2 (en) 2017-05-25 2024-10-31 Abbott Laboratories Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
JP7269182B2 (ja) 2017-05-30 2023-05-08 アボット・ラボラトリーズ 心臓トロポニンｉ及び早期バイオマーカーを使用する、ヒト対象における軽度外傷性脳損傷を診断及び査定する一助となるための方法
CA3068041C (en) 2017-07-03 2024-06-25 Abbott Laboratories Improved methods for measuring ubiquitin carboxy-terminal hydrolase l1 levels in blood
US11022617B2 (en) 2017-12-09 2021-06-01 Abbott Laboratories Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using glial fibrillary acidic protein (GFAP) and/or ubiquitin carboxy-terminal hydrolase L1 (UCH-L1)
EP3721234A1 (de) 2017-12-09 2020-10-14 Abbott Laboratories Verfahren zur unterstützung bei der diagnose und bewertung einer traumatischen hirnverletzung beim menschen mit einer kombination aus gfap und uch-l1
JP2021509120A (ja) 2017-12-28 2021-03-18 アスチュート メディカル，インコーポレイテッド Ｃｃｌ１４に関する抗体およびアッセイ
AU2018395255B2 (en) 2017-12-29 2025-02-20 Abbott Laboratories Novel biomarkers and methods for diagnosing and evaluating traumatic brain injury
CN112119151B (zh) 2018-03-02 2025-08-29 量子细胞公司 从组织中分离和表达分析感兴趣的区域的方法、组成和装置
US12235273B2 (en) 2018-05-04 2025-02-25 Abbott Laboratories HBV diagnostic, prognostic, and therapeutic methods and products
WO2020051231A1 (en) 2018-09-04 2020-03-12 H. Lee Moffitt Cancer Center & Research Institute Inc. Use of delta-tocotrienol for treating cancer
US12061200B2 (en) 2018-12-28 2024-08-13 Abbott Laboratories Direct detection of single molecules on microparticles
WO2020144535A1 (en) 2019-01-08 2020-07-16 Aduro Biotech Holdings, Europe B.V. Methods and compositions for treatment of multiple myeloma
US11079395B2 (en) 2019-03-01 2021-08-03 Abbott Laboratories Methods for predicting major adverse cardiovascular events in subjects with coronary artery disease
CA3132338A1 (en) 2019-04-05 2020-10-08 David Suhy Improved methods and compositions for synthetic biomarkers
US12582726B1 (en) 2019-04-05 2026-03-24 Earli Inc. Synthetic cancer-specific promoters
WO2021211331A1 (en) 2020-04-13 2021-10-21 Abbott Point Of Care Inc. METHODS, COMPLEXES AND KITS FOR DETECTING OR DETERMINING AN AMOUNT OF A ß-CORONAVIRUS ANTIBODY IN A SAMPLE
IL298008A (en) 2020-05-09 2023-01-01 Reata Pharmaceuticals Holdings Llc Methods for treating covid-19 with the help of bardoxolone methyl or its analogs
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
MX2022015287A (es) 2020-06-01 2023-02-22 Loop Diagnostics S L Metodo y kit para la deteccion temprana de septicemia.
EP4193149A1 (de) 2020-08-04 2023-06-14 Abbott Laboratories Verbesserte verfahren und kits zum nachweis von sars-cov-2-protein in einer probe
EP4193151A1 (de) 2020-08-04 2023-06-14 Abbott Rapid Diagnostics International Unlimited Company Assays zum nachweis von sars-cov-2
US20230407374A1 (en) * 2020-11-09 2023-12-21 Children's Medical Center Corporation Systems and methods for high throughput screening of molecular interactions
CA3198161A1 (en) 2020-12-01 2022-06-09 Beth MCQUISTON Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
WO2023102384A1 (en) 2021-11-30 2023-06-08 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
EP4259155A1 (de) 2020-12-11 2023-10-18 Reata Pharmaceuticals Holdings, LLC Synthetische triterpenoide zur verwendung in der therapie
EP4271998A1 (de) 2020-12-30 2023-11-08 Abbott Laboratories Verfahren zur bestimmung des sars-cov-2-antigens und anti-sars-cov-2-antikörpers in einer probe
US20220381796A1 (en) 2021-05-18 2022-12-01 Abbott Laboratories Methods of evaluating brain injury in a pediatric subject
EP4356129A1 (de) 2021-06-14 2024-04-24 Abbott Laboratories Verfahren zur diagnose oder unterstützung der diagnose von hirnverletzungen durch akustische energie, elektromagnetische energie, überdruckwelle und/oder explosionswind
EP4392783A1 (de) 2021-08-27 2024-07-03 Abbott Laboratories Verfahren zum nachweis von immunoglobulin g, subklassen 4 (igg4) in einer biologischen probe
CN118715440A (zh) 2021-08-31 2024-09-27 雅培实验室 诊断脑损伤的方法和系统
EP4396587A1 (de) 2021-08-31 2024-07-10 Abbott Laboratories Verfahren und systeme zur diagnose von hirnverletzungen
EP4409294A1 (de) 2021-09-30 2024-08-07 Abbott Laboratories Verfahren und systeme zur diagnose von hirnverletzungen
WO2023114978A1 (en) 2021-12-17 2023-06-22 Abbott Laboratories Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
WO2023144206A1 (en) 2022-01-27 2023-08-03 Sanofi Pasteur Modified vero cells and methods of using the same for virus production
EP4473311A1 (de) 2022-02-04 2024-12-11 Abbott Laboratories Lateralflussverfahren, tests und vorrichtungen zum nachweis oder zur messung der anwesenheit oder der menge von ubiquitincarboxyterminaler hydrolase l1 und/oder glialem fibrillärem saurem protein in einer probe
KR20250021400A (ko) 2022-04-29 2025-02-12 브로드윙 바이오 엘엘씨 보체 인자 h 관련 4-특이적 항체 및 그의 용도
EP4514845A1 (de) 2022-04-29 2025-03-05 Broadwing Bio LLC Bispezifische antikörper und verfahren zur behandlung von augenerkrankungen
EP4514470A1 (de) 2022-04-29 2025-03-05 Broadwing Bio LLC Angiopoietin-verwandte protein-7-spezifische antikörper und verwendungen davon
EP4587840A1 (de) 2022-09-15 2025-07-23 Abbott Laboratories Hbv-diagnostische, prognostische und therapeutische verfahren und produkte
JP2025532597A (ja) 2022-09-15 2025-10-01 アボット・ラボラトリーズ 軽度及び超軽度の外傷性脳損傷を区別するためのバイオマーカー及び方法
WO2024163477A1 (en) 2023-01-31 2024-08-08 University Of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections
WO2024211475A1 (en) 2023-04-04 2024-10-10 Abbott Laboratories Use of biomarkers to determine whether a subject has sustained, may have sustained or is suspected of sustaining a subacute acquired brain injury (abi)
EP4713682A1 (de) 2023-04-28 2026-03-25 Abbott Point of Care Inc. Verbesserte tests, kartuschen und kits zum nachweis von biomarkern, einschliesslich biomarkern für hirnverletzungen
WO2024227154A1 (en) 2023-04-28 2024-10-31 Broadwing Bio Llc Complement component 3 (c3)-specific antibodies and uses thereof
US12122842B1 (en) 2023-09-27 2024-10-22 R&D Systems, Inc. Human CD30-specific binding proteins and uses thereof
WO2025111147A1 (en) 2023-11-21 2025-05-30 Abbott Laboratories Two-dimensional matrix droplet array
WO2026024677A1 (en) 2024-07-22 2026-01-29 Abbott Laboratories Method for determining the plasma volume of a blood sample and method for determining the dilution of plasma
WO2026024668A1 (en) 2024-07-22 2026-01-29 Abbott Laboratories Method of determining a volume of a liquid in a sample
WO2026024666A1 (en) 2024-07-22 2026-01-29 Abbott Laboratories Systems and methods for digital detection assays

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL171930C (nl) * 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US4456716A (en) * 1982-12-29 1984-06-26 Ciba-Geigy Corporation 4-(Hydroxyphenylthio)imide stabilizers
FR2566271B1 (fr) * 1984-06-20 1986-11-07 Sanofi Sa Nouveaux conjugues cytotoxiques utilisables en therapeutique et procede d'obtention
US4981979A (en) * 1987-09-10 1991-01-01 Neorx Corporation Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity
US5068227A (en) * 1989-01-18 1991-11-26 Cyclex, Inc. Cyclodextrins as carriers
US5068277A (en) * 1989-05-03 1991-11-26 Rhone-Poulenc Inc. Hydrolyzable silicone polymers

Also Published As

Publication number Publication date
JPH06506688A (ja) 1994-07-28
AU1772992A (en) 1992-11-17
NO933581D0 (no) 1993-10-07
FI934437A0 (fi) 1993-10-08
DE69228682T2 (de) 1999-07-01
FI934437A7 (fi) 1993-11-22
NO933581L (no) 1993-12-10
EP0585310B1 (de) 1999-03-17
EP0585310A1 (de) 1994-03-09
DE69228682D1 (de) 1999-04-22
EP0585310A4 (de) 1995-06-14
CA2107894A1 (en) 1992-10-11
WO1992018868A1 (en) 1992-10-29
US5525524A (en) 1996-06-11
CA2107894C (en) 2003-10-14
FI934437L (fi) 1993-11-22

Similar Documents

Publication Publication Date Title
DE69228682D1 (de) "crosstalk"- oder übersprech-inhibitoren und ihre verwendung
DE3885220D1 (de) Toilette mit Vorrichtung zum Feststellen der Zusammensetzung von Urin.
AU7727491A (en) Improvements in or relating to methods for providing internal references for use in analyte-receptor assays
ES2094733T3 (es) Deteccion de enfermedades o disfunciones neurologicas.
DE69412137D1 (de) Sensoreinrichtung zum sandwichtest
DK0770876T3 (da) En screening-fremgangsmåde til at identificere ligander for målproteiner
CA2071904A1 (en) Antibodies to ligand analogues and their utility in ligand-receptor assays
ATE179799T1 (de) Vorrichtung zur analyse von haptenen und ihre verwendung
GB9013804D0 (en) Method for determining the relative heat affected zone("haz")toughness of steel
NO964015L (no) Fremgangsmåte for påvisning av kalpain-aktivering og identifisering av kalpain-inhibitorer
ATE237353T1 (de) Antikörper gegen p-selectin und ihre verwendung
CA2271544A1 (en) Method to detect bone and other connective tissue disorders in humans and animals
DE69214843D1 (de) Verfahren zum nachweis von beschädigungen des magenepithels
GR3032740T3 (en) Detection of antibody production
ATE130100T1 (de) Verfahren zur immunologischen erkennung maligner tumore und kit zur durchführung dieses verfahrens.
WO2000050455A3 (en) Antigen to systemic lupus erythematosis and diagnostic assay
HU910003D0 (en) Preparation for biological decreasing of oil stain
DE68906167D1 (de) Zusammensetzung zur erkennung von paradontalen krankheiten.
FR2599513B1 (fr) Anticorps monoclonaux inhibant la liaison de ige soluble aux lymphocytes humains, hybridomes monoclonaux produisant de tels anticorps, leur utilisation
AU7190894A (en) Phosphate assay
ATE141335T1 (de) Verfahren zur bestimmung des cholesterins, zum nachweis von gefässkrankheiten und zur anhebung des anteils an hdl-cholesterin
CA2026250A1 (en) Detection and quantification of neu related proteins in the biological fluids of humans
ATE148231T1 (de) Testsystem für degenerative muskelerkrankungen
ATE171545T1 (de) Verfahren zur bestimmung des lysingehaltes von samen
ATE118617T1 (de) Enzym-quantifizierungstest auf einem docht.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties